Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
August 08, 2024 at 07:02 AM EDT
The success of Eli Lilly's weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |